Free tool
FAERS Monitor: Retin-A-Micro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020475 or its brand name (Retin-A-Micro, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
6,689
Serious
4,179
62% of reports
Hospitalization
1,453
Death reported
854
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use889
- drug ineffective746
- pain498
- product use in unapproved indication485
- vomiting452
- paraesthesia374
- abdominal pain upper368
- rash366
- nausea354
- diarrhoea352
- headache339
- maternal exposure during pregnancy339
- taste disorder332
- gastrooesophageal reflux disease330
- hypoaesthesia328
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 33 |
| 2006 | 24 |
| 2007 | 40 |
| 2008 | 118 |
| 2009 | 75 |
| 2010 | 82 |
| 2011 | 102 |
| 2012 | 165 |
| 2013 | 107 |
| 2014 | 149 |
| 2015 | 236 |
| 2016 | 357 |
| 2017 | 371 |
| 2018 | 466 |
| 2019 | 364 |
| 2020 | 384 |
| 2021 | 428 |
| 2022 | 513 |
| 2023 | 573 |
| 2024 | 681 |
| 2025 | 815 |
| 2026 | 567 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,470 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 332 | 52.3 | 47.0 | 16,397 |
| gastrooesophageal reflux diseaseSignal | 330 | 12.9 | 11.6 | 3,622 |
| maternal exposure during pregnancySignal | 339 | 12.0 | 10.8 | 3,409 |
| paraesthesiaSignal | 374 | 7.5 | 6.8 | 2,108 |
| hypoaesthesiaSignal | 328 | 6.9 | 6.2 | 1,658 |
| product use in unapproved indicationSignal | 485 | 6.2 | 5.7 | 2,114 |
| abdominal pain upperSignal | 368 | 5.6 | 5.1 | 1,407 |
| off label useSignal | 889 | 3.2 | 3.0 | 1,395 |
| vomitingSignal | 452 | 3.0 | 2.8 | 624 |
| rashSignal | 366 | 2.6 | 2.4 | 379 |
| painSignal | 498 | 2.6 | 2.3 | 482 |
| drug ineffective | 746 | 1.8 | 1.7 | 271 |
| diarrhoea | 352 | 1.7 | 1.5 | 107 |
| headache | 339 | 1.7 | 1.5 | 100 |
| nausea | 354 | 1.4 | 1.3 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.